Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice.

Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J, Remeniuk B, Schwedt T, Anderson T, Dodick D, Porreca F.

Cephalalgia. 2019 Sep 24:333102419877662. doi: 10.1177/0333102419877662. [Epub ahead of print]

PMID:
31550910
2.

Proposed new diagnostic criteria for chronic migraine.

Chalmer MA, Hansen TF, Lebedeva ER, Dodick DW, Lipton RB, Olesen J.

Cephalalgia. 2019 Sep 22:333102419877171. doi: 10.1177/0333102419877171. [Epub ahead of print]

PMID:
31544467
3.

Post-traumatic headache: epidemiology and pathophysiological insights.

Ashina H, Porreca F, Anderson T, Amin FM, Ashina M, Schytz HW, Dodick DW.

Nat Rev Neurol. 2019 Oct;15(10):607-617. doi: 10.1038/s41582-019-0243-8. Epub 2019 Sep 16. Review.

PMID:
31527806
4.

Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.

Lipton RB, Munjal S, Buse DC, Alam A, Fanning KM, Reed ML, Schwedt TJ, Dodick DW.

Headache. 2019 Sep;59(8):1310-1323. doi: 10.1111/head.13588. Epub 2019 Aug 13.

5.

World Brain Day 2019: migraine, the painful truth.

Wijeratne T, Grisold W, Dodick D, Carroll W.

Lancet Neurol. 2019 Oct;18(10):914. doi: 10.1016/S1474-4422(19)30281-9. Epub 2019 Jul 22. No abstract available.

PMID:
31345666
6.

Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.

Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E.

Headache. 2019 Sep;59(8):1229-1239. doi: 10.1111/head.13608. Epub 2019 Jul 25.

7.

World Brain Day 2019; migraine - the painful truth.

Wijeratne T, Dodick D, Grisold W, Carroll W.

Eur J Neurol. 2019 Nov;26(11):e92-e93. doi: 10.1111/ene.14045. Epub 2019 Aug 16. No abstract available.

PMID:
31329327
8.

Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache.

Kopruszinski CM, Navratilova E, Vagnerova B, Swiokla J, Patwardhan A, Dodick D, Porreca F.

Cephalalgia. 2019 Jul 16:333102419865252. doi: 10.1177/0333102419865252. [Epub ahead of print]

PMID:
31311288
9.

Trial of Galcanezumab in Prevention of Episodic Cluster Headache.

Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM.

N Engl J Med. 2019 Jul 11;381(2):132-141. doi: 10.1056/NEJMoa1813440.

PMID:
31291515
10.

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.

Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.

Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.

PMID:
31234642
11.

Pathophysiology, prevention, and treatment of medication overuse headache.

Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T.

Lancet Neurol. 2019 Sep;18(9):891-902. doi: 10.1016/S1474-4422(19)30146-2. Epub 2019 Jun 4. Review.

PMID:
31174999
12.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30.

PMID:
31146544
13.

Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.

Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.

Cephalalgia. 2019 Jul;39(8):945-956. doi: 10.1177/0333102418825382. Epub 2019 May 21.

PMID:
31112399
14.

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD.

Headache. 2019 Sep;59(8):1240-1252. doi: 10.1111/head.13551. Epub 2019 May 9.

15.

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):939-944. doi: 10.1136/jnnp-2018-320242. Epub 2019 Apr 19.

16.

Tau Positron-Emission Tomography in Former National Football League Players.

Stern RA, Adler CH, Chen K, Navitsky M, Luo J, Dodick DW, Alosco ML, Tripodis Y, Goradia DD, Martin B, Mastroeni D, Fritts NG, Jarnagin J, Devous MD Sr, Mintun MA, Pontecorvo MJ, Shenton ME, Reiman EM.

N Engl J Med. 2019 May 2;380(18):1716-1725. doi: 10.1056/NEJMoa1900757. Epub 2019 Apr 10.

PMID:
30969506
17.

Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists.

Rau JC, Dodick DW.

Curr Treat Options Neurol. 2019 Mar 18;21(4):17. doi: 10.1007/s11940-019-0559-0. Review.

PMID:
30880363
18.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

19.

Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study.

Dodick DW, Reed ML, Fanning KM, Munjal S, Alam A, Buse DC, Schwedt TJ, Lipton RB.

Cephalalgia. 2019 Jun;39(7):873-882. doi: 10.1177/0333102418825346. Epub 2019 Feb 7.

PMID:
30732460
20.

Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.

Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ.

Headache. 2019 Apr;59(4):509-517. doi: 10.1111/head.13482. Epub 2019 Jan 30.

21.

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.

Dodick DW.

Cephalalgia. 2019 Mar;39(3):445-458. doi: 10.1177/0333102418821662. Epub 2019 Jan 19. Erratum in: Cephalalgia. 2019 Jul;39(8):1069.

PMID:
30661365
22.

Proceedings from the Ice Hockey Summit III: Action on Concussion.

Smith AM, Alford PA, Aubry M, Benson B, Black A, Brooks A, Burke C, D'Arcy R, Dodick D, Eaves M, Eickhoff C, Erredge K, Farrell K, Finnoff J, Fraser DD, Giza C, Greenwald RM, Hoshizaki B, Huston J, Jorgensen J, Joyner M, Krause D, LaVoi N, Leaf M, Leddy J, Margarucci K, Margulies S, Mihalik J, Munce T, Oeur A, Prideaux C, Roberts WO, Shen F, Soma D, Tabrum M, Stuart MB, Wethe J, Whitehead JR, Wiese-Bjornstal D, Stuart MJ.

Curr Sports Med Rep. 2019 Jan;18(1):23-34. doi: 10.1249/JSR.0000000000000557.

PMID:
30624332
23.

Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker.

Dodick DW, Tepper SJ, Lipton RB, Buse DC, Stewart WF, Bayliss M, Desai P, Sapra S, Anderson K, McInerney-Prichard E.

Headache. 2018 Oct;58(9):1358-1372. doi: 10.1111/head.13426.

PMID:
30362524
24.

Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.

Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML, Schwedt TJ, Dodick DW.

Headache. 2018 Oct;58(9):1408-1426. doi: 10.1111/head.13407. Epub 2018 Oct 20.

PMID:
30341895
25.

Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache.

Nation KM, Dodick DW, Navratilova E, Porreca F.

Cephalalgia. 2019 Apr;39(5):617-625. doi: 10.1177/0333102418804157. Epub 2018 Oct 4.

PMID:
30286616
26.

Functional outcome and survival following spontaneous intracerebral hemorrhage: A retrospective population-based study.

Øie LR, Madsbu MA, Solheim O, Jakola AS, Giannadakis C, Vorhaug A, Padayachy L, Jensberg H, Dodick D, Salvesen Ø, Gulati S.

Brain Behav. 2018 Oct;8(10):e01113. doi: 10.1002/brb3.1113. Epub 2018 Sep 21.

27.

A Cross-Study Analysis for Reproducible Sub-classification of Traumatic Brain Injury.

Si B, Dumkrieger G, Wu T, Zafonte R, Dodick DW, Schwedt TJ, Li J.

Front Neurol. 2018 Aug 13;9:606. doi: 10.3389/fneur.2018.00606. eCollection 2018.

28.

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days.

VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, Bigal ME.

Neurology. 2018 Sep 18;91(12):e1152-e1165. doi: 10.1212/01.wnl.0000544321.19316.40. Epub 2018 Aug 17.

29.

Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomes.

Si B, Dumkrieger G, Wu T, Zafonte R, Valadka AB, Okonkwo DO, Manley GT, Wang L, Dodick DW, Schwedt TJ, Li J.

PLoS One. 2018 Jul 11;13(7):e0198741. doi: 10.1371/journal.pone.0198741. eCollection 2018.

30.

Vancouver Declaration on Global Headache Patient Advocacy 2018.

Dodick D, Edvinsson L, Makino T, Grisold W, Sakai F, Jensen R, Balch A, Ruiz de la Torre E, Henscheid-Lorenz D, Craven A, Ashina M.

Cephalalgia. 2018 Nov;38(13):1899-1909. doi: 10.1177/0333102418781644. Epub 2018 Jun 8.

PMID:
29882695
31.

Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR.

JAMA Neurol. 2018 Sep 1;75(9):1080-1088. doi: 10.1001/jamaneurol.2018.1212. Erratum in: JAMA Neurol. 2019 Jul 1;76(7):872.

32.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

33.

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.

Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, Dodick DW, Lipton RB.

J Headache Pain. 2018 May 24;19(1):38. doi: 10.1186/s10194-018-0865-z.

34.

Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.

Dodick DW, Tepper SJ, Friedman DI, Gelfand AA, Kellerman DJ, Schmidt PC.

Headache. 2018 Jul;58(7):986-992. doi: 10.1111/head.13327. Epub 2018 May 21.

35.

The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.

Chen TY, Garza I, Dodick DW, Robertson CE.

Headache. 2018 Jul;58(7):973-985. doi: 10.1111/head.13317. Epub 2018 May 15.

PMID:
29762872
36.

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.

Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW.

Cephalalgia. 2019 Jan;39(1):52-60. doi: 10.1177/0333102418772585. Epub 2018 May 3.

PMID:
29722276
37.

Treatment of Cluster Headache.

Kingston WS, Dodick DW.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S9-S15. doi: 10.4103/aian.AIAN_17_18. Review.

38.

A Phase-by-Phase Review of Migraine Pathophysiology.

Dodick DW.

Headache. 2018 May;58 Suppl 1:4-16. doi: 10.1111/head.13300.

PMID:
29697154
39.

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.

Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, Villa G, Shah N, Tepper S, Dodick D.

J Med Econ. 2018 Jul;21(7):666-675. doi: 10.1080/13696998.2018.1457533. Epub 2018 Apr 3.

40.

Migraine.

Dodick DW.

Lancet. 2018 Mar 31;391(10127):1315-1330. doi: 10.1016/S0140-6736(18)30478-1. Epub 2018 Mar 6. Review.

PMID:
29523342
41.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

42.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
43.

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA.

Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22.

PMID:
29471679
44.

Measurement and implications of the distance between the sphenopalatine ganglion and nasal mucosa: a neuroimaging study.

Crespi J, Bratbak D, Dodick D, Matharu M, Jamtøy KA, Aschehoug I, Tronvik E.

J Headache Pain. 2018 Feb 13;19(1):14. doi: 10.1186/s10194-018-0843-5.

45.

King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletes.

Dhawan PS, Leong D, Tapsell L, Starling AJ, Galetta SL, Balcer LJ, Overall TL, Adler JS, Halker-Singh RB, Vargas BB, Dodick D.

Neurol Clin Pract. 2017 Dec;7(6):464-473. doi: 10.1212/CPJ.0000000000000381.

46.

Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.

Nation KM, De Felice M, Hernandez PI, Dodick DW, Neugebauer V, Navratilova E, Porreca F.

Pain. 2018 May;159(5):919-928. doi: 10.1097/j.pain.0000000000001167.

47.

Depicting the pterygopalatine ganglion on 3 Tesla magnetic resonance images.

Bratbak DF, Folvik M, Nordgård S, Stovner LJ, Dodick DW, Matharu M, Tronvik E.

Surg Radiol Anat. 2018 Jun;40(6):689-695. doi: 10.1007/s00276-017-1960-6. Epub 2017 Dec 22.

PMID:
29274037
48.

Academic dissertations from the Danish Headache Center 1980-2016.

Dodick DW.

Cephalalgia. 2017 Dec;37(2_suppl):3. doi: 10.1177/0333102417724937. No abstract available.

PMID:
29256258
49.

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW.

JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859. Erratum in: JAMA Neurol. 2018 Feb 1;75(2):260.

50.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

Supplemental Content

Loading ...
Support Center